These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 10955786)

  • 1. Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies.
    Hudes GR; Szarka CE; Adams A; Ranganathan S; McCauley RA; Weiner LM; Langer CJ; Litwin S; Yeslow G; Halberr T; Qian M; Gallo JM
    Clin Cancer Res; 2000 Aug; 6(8):3071-80. PubMed ID: 10955786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical trial of perillyl alcohol administered daily.
    Ripple GH; Gould MN; Stewart JA; Tutsch KD; Arzoomanian RZ; Alberti D; Feierabend C; Pomplun M; Wilding G; Bailey HH
    Clin Cancer Res; 1998 May; 4(5):1159-64. PubMed ID: 9607573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day.
    Ripple GH; Gould MN; Arzoomanian RZ; Alberti D; Feierabend C; Simon K; Binger K; Tutsch KD; Pomplun M; Wahamaki A; Marnocha R; Wilding G; Bailey HH
    Clin Cancer Res; 2000 Feb; 6(2):390-6. PubMed ID: 10690515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days.
    Bailey HH; Wilding G; Tutsch KD; Arzoomanian RZ; Alberti D; Feierabend C; Simon K; Marnocha R; Holstein SA; Stewart J; Lewis KA; Hohl RJ
    Cancer Chemother Pharmacol; 2004 Oct; 54(4):368-76. PubMed ID: 15205914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee.
    Vigushin DM; Poon GK; Boddy A; English J; Halbert GW; Pagonis C; Jarman M; Coombes RC
    Cancer Chemother Pharmacol; 1998; 42(2):111-7. PubMed ID: 9654110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of perillyl alcohol in patients with refractory malignancies.
    Murren JR; Pizzorno G; DiStasio SA; McKeon A; Peccerillo K; Gollerkari A; McMurray W; Burtness BA; Rutherford T; Li X; Ho PT; Sartorelli A
    Cancer Biol Ther; 2002; 1(2):130-5. PubMed ID: 12170772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gas chromatographic-mass spectrometric analysis of perillyl alcohol and metabolites in plasma.
    Zhang Z; Chen H; Chan KK; Budd T; Ganapathi R
    J Chromatogr B Biomed Sci Appl; 1999 May; 728(1):85-95. PubMed ID: 10379660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of perillyl alcohol administered four times daily continuously.
    Morgan-Meadows S; Dubey S; Gould M; Tutsch K; Marnocha R; Arzoomanin R; Alberti D; Binger K; Feierabend C; Volkman J; Ellingen S; Black S; Pomplun M; Wilding G; Bailey H
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):361-6. PubMed ID: 12904896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer.
    Bailey HH; Attia S; Love RR; Fass T; Chappell R; Tutsch K; Harris L; Jumonville A; Hansen R; Shapiro GR; Stewart JA
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):149-57. PubMed ID: 17885756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I trial of perillyl alcohol in patients with advanced solid tumors.
    Azzoli CG; Miller VA; Ng KK; Krug LM; Spriggs DR; Tong WP; Riedel ER; Kris MG
    Cancer Chemother Pharmacol; 2003 Jun; 51(6):493-8. PubMed ID: 12695855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.
    Dhodapkar M; Rubin J; Reid JM; Burch PA; Pitot HC; Buckner JC; Ames MM; Suman VJ
    Clin Cancer Res; 1997 Jul; 3(7):1093-100. PubMed ID: 9815788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxicity and biotransformation of the anticancer drug perillyl alcohol in PC12 cells and in the rat.
    Boon PJ; van der Boon D; Mulder GJ
    Toxicol Appl Pharmacol; 2000 Aug; 167(1):55-62. PubMed ID: 10936079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous measurement of perillyl alcohol and its metabolite perillic acid in plasma and lung after inhalational administration in Wistar rats.
    de Lima DC; Rodrigues SV; Boaventura GT; Cho HY; Chen TC; Schönthal AH; Da Fonseca CO
    Drug Test Anal; 2020 Feb; 12(2):268-279. PubMed ID: 31800149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of temozolomide using an extended continuous oral schedule.
    Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
    Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perillyl alcohol and perillic acid induced cell cycle arrest and apoptosis in non small cell lung cancer cells.
    Yeruva L; Pierre KJ; Elegbede A; Wang RC; Carper SW
    Cancer Lett; 2007 Nov; 257(2):216-26. PubMed ID: 17888568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. R-Limonene metabolism in humans and metabolite kinetics after oral administration.
    Schmidt L; Göen T
    Arch Toxicol; 2017 Mar; 91(3):1175-1185. PubMed ID: 27325307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.
    Stevenson JP; Rosen M; Sun W; Gallagher M; Haller DG; Vaughn D; Giantonio B; Zimmer R; Petros WP; Stratford M; Chaplin D; Young SL; Schnall M; O'Dwyer PJ
    J Clin Oncol; 2003 Dec; 21(23):4428-38. PubMed ID: 14645433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Na/K-ATPase as a target for anticancer drugs: studies with perillyl alcohol.
    Garcia DG; de Castro-Faria-Neto HC; da Silva CI; de Souza e Souza KF; Gonçalves-de-Albuquerque CF; Silva AR; de Amorim LM; Freire AS; Santelli RE; Diniz LP; Gomes FC; Faria MV; Burth P
    Mol Cancer; 2015 May; 14():105. PubMed ID: 25976744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of perillic acid in humans after a single dose administration of a citrus preparation rich in d-limonene content.
    Chow HH; Salazar D; Hakim IA
    Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1472-6. PubMed ID: 12433729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.